Research ArticleANTIBODY THERAPEUTICS

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

See allHide authors and affiliations

Science Translational Medicine  05 Nov 2014:
Vol. 6, Issue 261, pp. 261ra154
DOI: 10.1126/scitranslmed.3009835

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A Two-Pronged Approach for Central Nervous System Therapeutics

The brain has been considered off-limits to antibody therapies because of the blood-brain barrier (BBB), which protects the brain from circulating toxins while selectively transporting essential molecules into the brain. Efforts to use natural transport mechanisms to deliver antibody therapies into the brain have been successful in rodents. Whether a similar approach can be used in primates, including humans, remains unknown. Using bispecific antibodies with one arm binding to the transferrin receptor and the other to an Alzheimer’s disease drug target, we show that therapeutic antibodies can effectively and safely cross the BBB and enter the primate brain, thus paving the way for antibody therapeutics to treat central nervous system diseases in humans.

View Full Text